1 Min Read
Feb 21 (Reuters) - Bellicum Pharmaceuticals Inc:
* Bellicum Pharmaceuticals Inc- dosed first patient with BPX-601, first car t-cell product candidate to enter clinical studies Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.